Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

ResMed (RMD)

NYSE: RMD · Medical Devices · San Diego, CA

Our rating: Positive

Positive reaffirmed at $232.94, high conviction, November 2, 2026.

Breaks if: The Positive call is wrong if revenue growth decelerates below 6% year-on-year for two consecutive quarters, or if free cash flow margin drops below 23% for two straight quarters — either would indicate that GLP-1 headwinds or competitive normalization are biting faster than the current trajectory implies. On price, a sustained decline of more than 20% over the next twelve months without a corresponding reset in the earnings trajectory would also signal that the market is discounting a deterioration not yet visible in reported figures.

Key figures

Market value$33.1B
Revenue, last 12 months$5.7B
Net income, last 12 months$1.6B
Free cash flow, last 12 months$1.6B
Price to earnings20.8×
Free cash flow yield4.9%
Dividend yield1.1%
Operating margin33.0%
Return on equity26.4%
Beta to the S&P 5000.58
Volatility, annualized30.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.4B5.9%$2.92$374M
June 30, 2026$1.5B8.6%$2.64$404M
March 31, 2026$1.4B10.8%$2.74$520M
December 31, 2025$1.4B11.0%$2.68$311M
September 30, 2025$1.3B9.1%$2.37$414M
June 30, 2025$1.3B10.2%$2.58$508M
March 31, 2025$1.3B7.9%$2.48$558M
December 31, 2024$1.3B10.3%$2.34$288M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.